PDB Short entry for 1H28 HEADER CELL CYCLE/TRANSFERASE SUBSTRATE 31-JUL-02 1H28 TITLE CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM TITLE 2 P107 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 2, P33 PROTEIN KINASE, CDK2; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: CYCLIN A2; COMPND 8 CHAIN: B, D; COMPND 9 FRAGMENT: CYCLIN FOLD, RESIDUES 175-432; COMPND 10 SYNONYM: CYCLIN A; COMPND 11 ENGINEERED: YES; COMPND 12 MOL_ID: 3; COMPND 13 MOLECULE: RETINOBLASTOMA-LIKE PROTEIN 1; COMPND 14 CHAIN: E, F; COMPND 15 FRAGMENT: RB PEPTIDE, RESIDUES 653-663; COMPND 16 SYNONYM: 107 KDA RETINOBLASTOMA-ASSOCIATED PROTEIN, PRB1, P107, P107 COMPND 17 RECRUITMENT PEPTIDE 11MER; COMPND 18 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: PGEX; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 15 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 16 EXPRESSION_SYSTEM_PLASMID: PET21D; SOURCE 17 MOL_ID: 3; SOURCE 18 SYNTHETIC: YES; SOURCE 19 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 20 ORGANISM_COMMON: HUMAN; SOURCE 21 ORGANISM_TAXID: 9606 KEYWDS CELL CYCLE, PROTEIN KINASE, CYCLIN, CDK2, RECRUITMENT, PEPTIDE KEYWDS 2 SPECIFICITY, SERINE/THREONINE-PROTEIN KINASE, ATP-BINDING, CELL KEYWDS 3 DIVISION, MITOSIS, PHOSPHORYLATION, CELL CYCLE-TRANSFERASE KEYWDS 4 SUBSTRATE, CELL CYCLE-TRANSFERASE SUBSTRATE COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR I.TEWS,K.Y.CHENG,E.D.LOWE,M.E.M.NOBLE,N.R.BROWN,S.GUL,S.GAMBLIN, AUTHOR 2 L.N.JOHNSON REVDAT 4 13-DEC-23 1H28 1 LINK REVDAT 3 13-JUL-11 1H28 1 VERSN REVDAT 2 24-FEB-09 1H28 1 VERSN REVDAT 1 01-FEB-03 1H28 0 JRNL AUTH E.D.LOWE,I.TEWS,K.Y.CHENG,N.R.BROWN,S.GUL,M.E.M.NOBLE, JRNL AUTH 2 S.GAMBLIN,L.N.JOHNSON JRNL TITL SPECIFICITY DETERMINANTS OF RECRUITMENT PEPTIDES BOUND TO JRNL TITL 2 PHOSPHO-CDK2/CYCLIN A JRNL REF BIOCHEMISTRY V. 41 15625 2002 JRNL REFN ISSN 0006-2960 JRNL PMID 12501191 JRNL DOI 10.1021/BI0268910 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH N.R.BROWN,M.E.M.NOBLE,J.A.ENDICOTT,L.N.JOHNSON REMARK 1 TITL THE STRUCTURAL BASIS FOR SPECIFICITY OF SUBSTRATE AND REMARK 1 TITL 2 RECRUITMENT PEPTIDES FOR CYCLIN-DEPENDANT KINASES REMARK 1 REF NAT.CELL BIOL. V. 1 438 1999 REMARK 1 REFN ISSN 1465-7392 REMARK 1 PMID 10559988 REMARK 1 DOI 10.1038/15674 REMARK 2 REMARK 2 RESOLUTION. 2.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.62 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 95.1 REMARK 3 NUMBER OF REFLECTIONS : 39408 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.247 REMARK 3 R VALUE (WORKING SET) : 0.243 REMARK 3 FREE R VALUE : 0.323 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 2095 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 9088 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 37 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.76 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.07000 REMARK 3 B22 (A**2) : 0.06000 REMARK 3 B33 (A**2) : 0.01000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 1.245 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.450 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.260 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 13.287 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1H28 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 31-JUL-02. REMARK 100 THE DEPOSITION ID IS D_1290011187. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-MAR-02 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.934 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 41507 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.800 REMARK 200 RESOLUTION RANGE LOW (A) : 28.990 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.7 REMARK 200 DATA REDUNDANCY : 2.200 REMARK 200 R MERGE (I) : 0.16600 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 2.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.95 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.8 REMARK 200 DATA REDUNDANCY IN SHELL : 2.10 REMARK 200 R MERGE FOR SHELL (I) : 0.61700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1QMZ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 65.70 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.60 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.8M KCL, 1.2M (NH4)2SO4, 40MM HEPES REMARK 280 PH 7.0. PROTEIN CONCENTRATION = 10MG/ML, PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 74.75150 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 81.25700 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 74.75150 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 81.25700 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CDK2: CONTROL OF THE CELL CYCLE DURING S PHASE AND G2. REMARK 400 BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES. REMARK 400 REMARK 400 CYCLIN A2: CONTROL OF THE CELL CYCLE. INTERACTS WITH THE CDK2 REMARK 400 AND CDC2 PROTEIN KINASES. REMARK 400 REMARK 400 P107: INVOLVED IN G1 ARREST. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -4 REMARK 465 PRO A -3 REMARK 465 LEU A -2 REMARK 465 GLY A -1 REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 GLU B 174 REMARK 465 GLY C -4 REMARK 465 PRO C -3 REMARK 465 LEU C -2 REMARK 465 GLY C -1 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 GLU D 174 REMARK 465 ALA E 653 REMARK 465 ALA F 653 REMARK 465 GLY F 654 REMARK 465 SER F 655 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O ALA A 277 N ALA A 279 1.76 REMARK 500 ND1 HIS D 321 OG SER D 375 1.87 REMARK 500 OD1 ASN D 415 N LYS D 417 1.89 REMARK 500 O VAL D 175 N ASP D 177 2.00 REMARK 500 O ILE C 49 OG SER C 53 2.03 REMARK 500 OD2 ASP A 247 OG SER A 249 2.06 REMARK 500 OE2 GLU A 224 OG1 THR A 231 2.07 REMARK 500 O MET A 1 O HOH A 2002 2.07 REMARK 500 O THR A 72 N ASN A 74 2.07 REMARK 500 O LEU C 296 O HOH C 2010 2.08 REMARK 500 OE1 GLU A 81 NZ LYS A 142 2.10 REMARK 500 NZ LYS B 266 OE1 GLU B 295 2.11 REMARK 500 NZ LYS A 129 OG1 THR A 165 2.11 REMARK 500 O LEU D 376 OG1 THR D 380 2.16 REMARK 500 O GLU A 40 NZ LYS B 288 2.18 REMARK 500 O LEU D 306 N ALA D 308 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O LYS B 379 NH2 ARG D 378 2665 1.84 REMARK 500 NH1 ARG B 378 O LEU D 320 2665 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 TPO A 160 C HIS A 161 N 0.246 REMARK 500 MET D 261 CG MET D 261 SD 0.159 REMARK 500 PHE D 267 CE2 PHE D 267 CD2 -0.156 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 86 CB - CG - OD2 ANGL. DEV. = 6.9 DEGREES REMARK 500 TYR A 159 O - C - N ANGL. DEV. = -16.5 DEGREES REMARK 500 HIS A 161 C - N - CA ANGL. DEV. = -25.0 DEGREES REMARK 500 ASP A 185 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP A 206 CB - CG - OD2 ANGL. DEV. = 6.0 DEGREES REMARK 500 ASP A 210 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES REMARK 500 ASP A 247 CB - CG - OD2 ANGL. DEV. = 5.9 DEGREES REMARK 500 ASP A 270 CB - CG - OD2 ANGL. DEV. = 6.9 DEGREES REMARK 500 ASP B 181 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP B 205 CB - CG - OD2 ANGL. DEV. = 6.8 DEGREES REMARK 500 ASP B 283 CB - CG - OD2 ANGL. DEV. = 7.8 DEGREES REMARK 500 ASP B 305 CB - CG - OD2 ANGL. DEV. = 6.8 DEGREES REMARK 500 ASP B 345 CB - CG - OD2 ANGL. DEV. = 7.7 DEGREES REMARK 500 ASP B 393 CB - CG - OD2 ANGL. DEV. = 6.0 DEGREES REMARK 500 LEU C 76 CA - CB - CG ANGL. DEV. = 13.9 DEGREES REMARK 500 ASP C 86 CB - CG - OD2 ANGL. DEV. = 6.2 DEGREES REMARK 500 ASP C 92 CB - CG - OD2 ANGL. DEV. = 5.9 DEGREES REMARK 500 ASP C 127 CB - CG - OD2 ANGL. DEV. = 8.3 DEGREES REMARK 500 TPO C 160 CA - C - N ANGL. DEV. = 17.9 DEGREES REMARK 500 TPO C 160 O - C - N ANGL. DEV. = -38.4 DEGREES REMARK 500 ARG C 169 NE - CZ - NH2 ANGL. DEV. = -3.5 DEGREES REMARK 500 ASP C 206 CB - CG - OD2 ANGL. DEV. = 6.4 DEGREES REMARK 500 ASP C 210 CB - CG - OD2 ANGL. DEV. = 6.6 DEGREES REMARK 500 ASP C 247 CB - CG - OD2 ANGL. DEV. = 8.7 DEGREES REMARK 500 ASP C 256 CB - CG - OD2 ANGL. DEV. = 6.5 DEGREES REMARK 500 ASP D 177 CB - CG - OD2 ANGL. DEV. = 6.3 DEGREES REMARK 500 ASP D 216 CB - CG - OD2 ANGL. DEV. = 5.4 DEGREES REMARK 500 LEU D 243 CA - CB - CG ANGL. DEV. = 13.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 2 -14.38 -49.69 REMARK 500 THR A 14 -83.42 23.81 REMARK 500 LEU A 37 -97.42 -103.12 REMARK 500 ASP A 38 122.76 93.82 REMARK 500 GLU A 40 -35.22 83.20 REMARK 500 THR A 41 -169.71 -67.83 REMARK 500 PRO A 61 -34.12 -37.45 REMARK 500 GLU A 73 -49.47 49.62 REMARK 500 HIS A 84 -60.09 -28.22 REMARK 500 CYS A 118 -71.69 -40.32 REMARK 500 ASP A 127 59.19 -162.82 REMARK 500 THR A 137 -42.56 -18.18 REMARK 500 LEU A 143 143.50 -31.57 REMARK 500 ALA A 144 -159.87 -153.46 REMARK 500 ASP A 145 88.57 20.57 REMARK 500 TYR A 159 -162.22 -112.11 REMARK 500 VAL A 164 137.31 70.46 REMARK 500 LEU A 175 25.74 -64.17 REMARK 500 SER A 181 -138.60 -148.06 REMARK 500 PHE A 193 -76.16 -45.92 REMARK 500 ALA A 201 132.86 -33.94 REMARK 500 LEU A 202 -71.42 -67.48 REMARK 500 PHE A 203 76.34 -109.43 REMARK 500 TRP A 227 68.98 -166.35 REMARK 500 THR A 231 12.57 -69.68 REMARK 500 PHE A 240 152.15 -34.50 REMARK 500 TRP A 243 175.45 -59.47 REMARK 500 ASP A 256 -157.83 -70.09 REMARK 500 LEU A 267 46.34 -78.79 REMARK 500 ALA A 277 -137.23 -68.86 REMARK 500 LYS A 278 -42.61 4.60 REMARK 500 PRO B 176 -9.01 -55.45 REMARK 500 HIS B 179 -73.61 -51.54 REMARK 500 ARG B 187 -8.84 -53.43 REMARK 500 GLU B 190 -71.53 -42.16 REMARK 500 VAL B 191 -38.79 -30.63 REMARK 500 VAL B 197 -82.98 -40.41 REMARK 500 SER B 245 -26.05 -149.05 REMARK 500 SER B 265 -74.61 -59.62 REMARK 500 TYR B 271 73.97 -114.05 REMARK 500 PRO B 273 152.85 -48.72 REMARK 500 ASP B 284 17.08 57.43 REMARK 500 PHE B 304 17.69 56.69 REMARK 500 ALA B 307 57.32 -92.69 REMARK 500 LEU B 320 -34.73 -29.91 REMARK 500 ALA B 325 151.87 -47.34 REMARK 500 ASN B 326 93.60 -160.39 REMARK 500 LEU B 336 -74.12 -45.46 REMARK 500 TYR B 347 -18.36 -39.84 REMARK 500 HIS B 361 -73.60 -59.35 REMARK 500 REMARK 500 THIS ENTRY HAS 121 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 TYR A 159 -24.58 REMARK 500 TPO C 160 -41.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN E OF RETINOBLASTOMA-LIKE REMARK 800 PROTEIN 1 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN F OF RETINOBLASTOMA-LIKE REMARK 800 PROTEIN 1 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H06 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0U RELATED DB: PDB REMARK 900 M. SMEGMATIS ARYLAMINE N-ACETYL TRANSFERASE REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 11 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 11 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 11 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H- INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{ 4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2- DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2-ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3- THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO -2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 999 REMARK 999 SEQUENCE REMARK 999 MOLECULE IS A TRUNCATED FRAGMENT OF CYCLIN A3 CONSISTING OF REMARK 999 RESIDUES 175-432 DBREF 1H28 A -4 0 PDB 1H28 1H28 -4 0 DBREF 1H28 A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1H28 B 175 432 UNP P20248 CGA2_HUMAN 175 432 DBREF 1H28 C -4 0 PDB 1H28 1H28 -4 0 DBREF 1H28 C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1H28 D 175 432 UNP P20248 CGA2_HUMAN 175 432 DBREF 1H28 E 653 663 UNP P28749 RBL1_HUMAN 653 663 DBREF 1H28 F 653 663 UNP P28749 RBL1_HUMAN 653 663 SEQRES 1 A 303 GLY PRO LEU GLY SER MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 A 303 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 A 303 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 A 303 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 A 303 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 A 303 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 A 303 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 A 303 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 A 303 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 A 303 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 A 303 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 A 303 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 A 303 PHE GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL SEQRES 14 A 303 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 A 303 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 A 303 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 A 303 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 A 303 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 A 303 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 A 303 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 A 303 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 A 303 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 A 303 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 A 303 HIS LEU ARG LEU SEQRES 1 B 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 B 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 B 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 B 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 B 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 B 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 B 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 B 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 B 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 B 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 B 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 B 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 B 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 B 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 B 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 B 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 B 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 B 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 B 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 B 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 303 GLY PRO LEU GLY SER MET GLU ASN PHE GLN LYS VAL GLU SEQRES 2 C 303 LYS ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA SEQRES 3 C 303 ARG ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS SEQRES 4 C 303 ILE ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR SEQRES 5 C 303 ALA ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS SEQRES 6 C 303 PRO ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU SEQRES 7 C 303 ASN LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP SEQRES 8 C 303 LEU LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE SEQRES 9 C 303 PRO LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU SEQRES 10 C 303 GLN GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS SEQRES 11 C 303 ARG ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU SEQRES 12 C 303 GLY ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA SEQRES 13 C 303 PHE GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL SEQRES 14 C 303 THR LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS SEQRES 15 C 303 LYS TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY SEQRES 16 C 303 CYS ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE SEQRES 17 C 303 PRO GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE SEQRES 18 C 303 ARG THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY SEQRES 19 C 303 VAL THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS SEQRES 20 C 303 TRP ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU SEQRES 21 C 303 ASP GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS SEQRES 22 C 303 TYR ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU SEQRES 23 C 303 ALA HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO SEQRES 24 C 303 HIS LEU ARG LEU SEQRES 1 D 259 GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU SEQRES 2 D 259 ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR SEQRES 3 D 259 MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA SEQRES 4 D 259 ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR SEQRES 5 D 259 LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR SEQRES 6 D 259 ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY SEQRES 7 D 259 LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SEQRES 8 D 259 SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU SEQRES 9 D 259 PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN SEQRES 10 D 259 VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR SEQRES 11 D 259 PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR SEQRES 12 D 259 GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL SEQRES 13 D 259 GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE SEQRES 14 D 259 ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE SEQRES 15 D 259 ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR SEQRES 16 D 259 GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY SEQRES 17 D 259 TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU SEQRES 18 D 259 HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SEQRES 19 D 259 SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY SEQRES 20 D 259 VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 E 11 ALA GLY SER ALA LYS ARG ARG LEU PHE GLY GLU SEQRES 1 F 11 ALA GLY SER ALA LYS ARG ARG LEU PHE GLY GLU MODRES 1H28 TPO A 160 THR PHOSPHOTHREONINE MODRES 1H28 TPO C 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HET TPO C 160 11 HETNAM TPO PHOSPHOTHREONINE HETSYN TPO PHOSPHONOTHREONINE FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 7 HOH *37(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 ALA A 93 1 7 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 THR A 165 ARG A 169 5 5 HELIX 6 6 ALA A 170 LEU A 175 1 6 HELIX 7 7 THR A 182 ARG A 199 1 18 HELIX 8 8 SER A 207 GLY A 220 1 14 HELIX 9 9 GLY A 229 MET A 233 5 5 HELIX 10 10 ASP A 247 VAL A 252 1 6 HELIX 11 11 ASP A 256 LEU A 267 1 12 HELIX 12 12 HIS A 283 VAL A 289 5 7 HELIX 13 13 VAL B 175 ASP B 177 5 3 HELIX 14 14 TYR B 178 LYS B 194 1 17 HELIX 15 15 GLY B 198 GLN B 203 1 6 HELIX 16 16 THR B 207 TYR B 225 1 19 HELIX 17 17 GLN B 228 LEU B 243 1 16 HELIX 18 18 LEU B 249 GLU B 269 1 21 HELIX 19 19 GLU B 274 THR B 282 1 9 HELIX 20 20 THR B 287 LEU B 302 1 16 HELIX 21 21 THR B 310 LEU B 320 1 11 HELIX 22 22 ASN B 326 ASP B 343 1 18 HELIX 23 23 LEU B 351 GLY B 369 1 19 HELIX 24 24 PRO B 373 GLY B 381 1 9 HELIX 25 25 THR B 383 LYS B 400 1 18 HELIX 26 26 ALA B 401 HIS B 404 5 4 HELIX 27 27 GLN B 407 TYR B 413 1 7 HELIX 28 28 GLY B 420 LEU B 424 5 5 HELIX 29 29 SER C 0 GLU C 2 5 3 HELIX 30 30 PRO C 45 LYS C 56 1 12 HELIX 31 31 LEU C 87 SER C 94 1 8 HELIX 32 32 PRO C 100 HIS C 121 1 22 HELIX 33 33 LYS C 129 GLN C 131 5 3 HELIX 34 34 ALA C 170 LEU C 175 1 6 HELIX 35 35 SER C 181 ARG C 199 1 19 HELIX 36 36 SER C 207 GLY C 220 1 14 HELIX 37 37 GLY C 229 MET C 233 5 5 HELIX 38 38 ASP C 247 VAL C 252 1 6 HELIX 39 39 ASP C 256 LEU C 267 1 12 HELIX 40 40 SER C 276 LEU C 281 1 6 HELIX 41 41 HIS C 283 GLN C 287 5 5 HELIX 42 42 TYR D 178 CYS D 193 1 16 HELIX 43 43 GLY D 198 GLN D 203 5 6 HELIX 44 44 THR D 207 TYR D 225 1 19 HELIX 45 45 GLN D 228 LEU D 243 1 16 HELIX 46 46 LEU D 249 GLU D 269 1 21 HELIX 47 47 GLU D 274 THR D 282 1 9 HELIX 48 48 THR D 287 THR D 303 1 17 HELIX 49 49 THR D 310 PHE D 319 1 10 HELIX 50 50 LEU D 320 GLN D 322 5 3 HELIX 51 51 ASN D 326 ASP D 343 1 18 HELIX 52 52 ASP D 343 LEU D 348 1 6 HELIX 53 53 LEU D 351 GLY D 369 1 19 HELIX 54 54 PRO D 373 GLY D 381 1 9 HELIX 55 55 LEU D 387 ALA D 401 1 15 HELIX 56 56 GLN D 407 TYR D 413 1 7 HELIX 57 57 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 13 0 SHEET 2 AA 5 GLY A 16 ASN A 23 -1 O GLY A 16 N GLY A 13 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 THR A 72 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLU C 12 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ILE C 35 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LEU C 76 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C TYR A 159 N TPO A 160 1555 1555 1.35 LINK C TPO A 160 N HIS A 161 1555 1555 1.58 LINK C TYR C 159 N TPO C 160 1555 1555 1.66 LINK O TPO C 160 N HIS C 161 1555 1555 1.82 LINK C TPO C 160 N HIS C 161 1555 1555 1.46 CISPEP 1 VAL A 154 PRO A 155 0 3.47 CISPEP 2 GLN B 323 PRO B 324 0 -13.65 CISPEP 3 ASP B 345 PRO B 346 0 -9.96 CISPEP 4 VAL C 154 PRO C 155 0 4.04 CISPEP 5 GLN D 323 PRO D 324 0 -21.86 CISPEP 6 ASP D 345 PRO D 346 0 19.81 SITE 1 AC1 15 LEU A 96 HIS A 295 MET B 210 TRP B 217 SITE 2 AC1 15 GLU B 220 GLU B 224 GLY B 251 LYS B 252 SITE 3 AC1 15 GLN B 254 TYR B 280 ILE B 281 THR B 282 SITE 4 AC1 15 THR B 285 TYR B 286 SER C 239 SITE 1 AC2 18 LYS A 237 SER A 239 HIS C 295 MET D 210 SITE 2 AC2 18 TRP D 217 GLU D 220 GLU D 224 ARG D 250 SITE 3 AC2 18 GLY D 251 LYS D 252 GLN D 254 TYR D 280 SITE 4 AC2 18 ILE D 281 THR D 282 ASP D 283 THR D 285 SITE 5 AC2 18 TYR D 286 HOH F2001 CRYST1 149.503 162.514 71.375 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.006689 0.000000 0.000000 0.00000 SCALE2 0.000000 0.006153 0.000000 0.00000 SCALE3 0.000000 0.000000 0.014010 0.00000 MTRIX1 1 0.999990 -0.000490 0.003600 -0.03242 1 MTRIX2 1 -0.000480 -1.000000 -0.001210 0.00121 1 MTRIX3 1 0.003600 0.001210 -0.999990 -0.99999 1 MTRIX1 2 0.999990 0.000630 0.003450 -0.05151 1 MTRIX2 2 0.000620 -0.999990 0.004140 154.78839 1 MTRIX3 2 0.003450 -0.004140 -0.999990 35.96083 1